Non Small-Cell Lung Cancer Market - 2026-2031
Non Small-Cell Lung Cancer Market reached USD 25.4 billion in 2022 and is expected to reach USD 47.4 billion by 2031, growing with a CAGR of 8.40% during the forecast period 2026-2031.
The Non Small-Cell Lung Cancer Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.
A Non Small-Cell Lung Cancer Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.
By Drug Class
Both primary and secondary data sources have been used in the global Non Small-Cell Lung Cancer Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
The Non Small-Cell Lung Cancer Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.
A Non Small-Cell Lung Cancer Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.
By Drug Class
- Epidermal Growth Factor Receptor (EGFR) Inhibitors*
- Anaplastic Lymphoma Kinase (ALK) Inhibitors
- ROS1 Inhibitors
- BRAF Inhibitors
- Others
- Squamous Cell Carcinoma*
- Large Cell Carcinoma
- Adenocarcinoma
- Others
- Chemotherapy*
- Targeted Therapy
- Immunotherapy
- Hospitals*
- Homecare
- Specialty Clinics
- Others
- North America (U.S., Canada, Mexico)
- Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
- Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
- South America (Colombia, Brazil, Argentina, Rest of South America)
- Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
- Go-to-market Strategy.
- Neutral perspective on the market performance.
- Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.
- Customized regional/country reports as per request and country level analysis.
- Potential & niche segments and regions exhibiting promising growth covered.
- Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).
Both primary and secondary data sources have been used in the global Non Small-Cell Lung Cancer Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
1. METHODOLOGY AND SCOPE
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
3.1. Snippet by Drug Class
3.2. Snippet by Type
3.3. Snippet by Treatment
3.4. Snippet by End-user
3.5. Snippet by Region
4. DYNAMICS
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising FDA Approval for non-small-cell lung cancer treatment
4.1.2. Restraints
4.1.2.1. Side effects associated with non-small-cell lung cancer
4.1.3. Opportunity
4.1.3.1. Increasing research activities
4.1.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis
6. COVID-19 ANALYSIS
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion
7. RUSSIA-UKRAINE WAR ANALYSIS
8. ARTIFICIAL INTELLIGENCE ANALYSIS
9. BY DRUG CLASS
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
9.1.2. Market Attractiveness Index, By Drug Class
9.2. Epidermal Growth Factor Receptor (EGFR) Inhibitors*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Anaplastic Lymphoma Kinase (ALK) Inhibitors
9.4. ROS1 Inhibitors
9.5. BRAF Inhibitors
9.6. Others
10. BY TYPE
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.1.2. Market Attractiveness Index, By Type
10.2. Squamous Cell Carcinoma*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Large Cell Carcinoma
10.4. Adenocarcinoma
10.5. Others
11. BY TREATMENT
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
11.1.2. Market Attractiveness Index, By Treatment
11.2. Chemotherapy*
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Targeted Therapy
11.4. Immunotherapy
12. BY END-USER
12.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
12.2. Market Attractiveness Index, By End-user
12.3. Hospitals*
12.3.1. Introduction
12.3.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
12.4. Homecare
12.5. Specialty Clinics
12.6. Others
13. BY REGION
13.1. Introduction
13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
13.1.2. Market Attractiveness Index, By Region
13.2. North America
13.2.1. Introduction
13.2.2. Key Region-Specific Dynamics
13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
13.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
13.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
13.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.2.7.1. U.S.
13.2.7.2. Canada
13.2.7.3. Mexico
13.3. Europe
13.3.1. Introduction
13.3.2. Key Region-Specific Dynamics
13.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
13.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
13.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
13.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
13.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.3.7.1. Germany
13.3.7.2. U.K.
13.3.7.3. France
13.3.7.4. Italy
13.3.7.5. Spain
13.3.7.6. Rest of Europe
13.4. South America
13.4.1. Introduction
13.4.2. Key Region-Specific Dynamics
13.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
13.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
13.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
13.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
13.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.4.7.1. Brazil
13.4.7.2. Argentina
13.4.7.3. Rest of South America
13.5. Asia-Pacific
13.5.1. Introduction
13.5.2. Key Region-Specific Dynamics
13.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
13.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
13.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
13.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
13.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.5.7.1. China
13.5.7.2. India
13.5.7.3. Japan
13.5.7.4. Australia
13.5.7.5. Rest of Asia-Pacific
13.6. Middle East and Africa
13.6.1. Introduction
13.6.2. Key Region-Specific Dynamics
13.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
13.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
13.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
13.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
14. COMPETITIVE LANDSCAPE
14.1. Competitive Scenario
14.2. Product Benchmarking
14.3. Company Share Analysis
14.4. Key Developments and Strategies
15. COMPANY PROFILES
15.1. Eli Lilly and Company*
15.1.1. Company Overview
15.1.2. Product Portfolio and Description
15.1.3. Financial Overview
15.1.4. Key Developments
15.2. Sanofi
15.3. Novartis AG
15.4. F. Hoffmann-La Roche Ltd
15.5. Merck & Co., Inc.
15.6. Pfizer Inc.
15.7. AstraZeneca
15.8. Boehringer Ingelheim
15.9. Bristol-Myers Squibb Company
15.10. Astellas (*LIST NOT EXHAUSTIVE)
16. APPENDIX
16.1. About Us and Services
16.2. Contact Us
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
3.1. Snippet by Drug Class
3.2. Snippet by Type
3.3. Snippet by Treatment
3.4. Snippet by End-user
3.5. Snippet by Region
4. DYNAMICS
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising FDA Approval for non-small-cell lung cancer treatment
4.1.2. Restraints
4.1.2.1. Side effects associated with non-small-cell lung cancer
4.1.3. Opportunity
4.1.3.1. Increasing research activities
4.1.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis
6. COVID-19 ANALYSIS
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion
7. RUSSIA-UKRAINE WAR ANALYSIS
8. ARTIFICIAL INTELLIGENCE ANALYSIS
9. BY DRUG CLASS
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
9.1.2. Market Attractiveness Index, By Drug Class
9.2. Epidermal Growth Factor Receptor (EGFR) Inhibitors*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Anaplastic Lymphoma Kinase (ALK) Inhibitors
9.4. ROS1 Inhibitors
9.5. BRAF Inhibitors
9.6. Others
10. BY TYPE
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.1.2. Market Attractiveness Index, By Type
10.2. Squamous Cell Carcinoma*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Large Cell Carcinoma
10.4. Adenocarcinoma
10.5. Others
11. BY TREATMENT
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
11.1.2. Market Attractiveness Index, By Treatment
11.2. Chemotherapy*
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Targeted Therapy
11.4. Immunotherapy
12. BY END-USER
12.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
12.2. Market Attractiveness Index, By End-user
12.3. Hospitals*
12.3.1. Introduction
12.3.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
12.4. Homecare
12.5. Specialty Clinics
12.6. Others
13. BY REGION
13.1. Introduction
13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
13.1.2. Market Attractiveness Index, By Region
13.2. North America
13.2.1. Introduction
13.2.2. Key Region-Specific Dynamics
13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
13.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
13.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
13.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.2.7.1. U.S.
13.2.7.2. Canada
13.2.7.3. Mexico
13.3. Europe
13.3.1. Introduction
13.3.2. Key Region-Specific Dynamics
13.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
13.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
13.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
13.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
13.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.3.7.1. Germany
13.3.7.2. U.K.
13.3.7.3. France
13.3.7.4. Italy
13.3.7.5. Spain
13.3.7.6. Rest of Europe
13.4. South America
13.4.1. Introduction
13.4.2. Key Region-Specific Dynamics
13.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
13.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
13.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
13.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
13.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.4.7.1. Brazil
13.4.7.2. Argentina
13.4.7.3. Rest of South America
13.5. Asia-Pacific
13.5.1. Introduction
13.5.2. Key Region-Specific Dynamics
13.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
13.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
13.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
13.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
13.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.5.7.1. China
13.5.7.2. India
13.5.7.3. Japan
13.5.7.4. Australia
13.5.7.5. Rest of Asia-Pacific
13.6. Middle East and Africa
13.6.1. Introduction
13.6.2. Key Region-Specific Dynamics
13.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
13.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
13.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
13.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
14. COMPETITIVE LANDSCAPE
14.1. Competitive Scenario
14.2. Product Benchmarking
14.3. Company Share Analysis
14.4. Key Developments and Strategies
15. COMPANY PROFILES
15.1. Eli Lilly and Company*
15.1.1. Company Overview
15.1.2. Product Portfolio and Description
15.1.3. Financial Overview
15.1.4. Key Developments
15.2. Sanofi
15.3. Novartis AG
15.4. F. Hoffmann-La Roche Ltd
15.5. Merck & Co., Inc.
15.6. Pfizer Inc.
15.7. AstraZeneca
15.8. Boehringer Ingelheim
15.9. Bristol-Myers Squibb Company
15.10. Astellas (*LIST NOT EXHAUSTIVE)
16. APPENDIX
16.1. About Us and Services
16.2. Contact Us
